# US 2026/0224509 A1 · Treatment of Paranasal Sinus Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224509 A1
- Document ID: US20260224509A1
- Status: Published application
- Kind: A1
- Application number: 19/296,578
- Filed: 2025-08-11
- Published: 2026-08-06
- Earliest claimed: 2018-10-12
- Assignees: Cymbidium Medical LLC
- Applicants: Cymbidium Medical LLC
- Inventors: Harry Ross
- Web page: https://patentgrep.com/patent/US20260224509A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61B 17/24: for use in the oral cavity, larynx, bronchial passages or nose (for medical inspection of cavities or tubes in the body A61B1/00); Tongue scrapers
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61M 3/0262: {manually, e.g. by squeezing a bulb}
- A61M 3/0279: {Cannula; Nozzles; Tips; their connection means}
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 2202/04: Liquids
- A61M 2202/064: Powder
- A61M 2210/0618: Nose
- A61M 2210/0681: Sinus (maxillaris)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A method for the treatment of paranasal sinus disease, administering a treatment formulation or a drug treatment formulation through the nasal cavity directly into a paranasal sinus.

## Claims

### Claim 1

A method of treating a disease of a paranasal sinus, the method comprising
piercing a wall of the paranasal sinus with a needle syringe to form an opening,
inserting the needle syringe containing a treatment formulation through the opening and into the paranasal sinus, and
delivering the treatment formulation to the paranasal sinus.

### Claim 2

A method of delivering a drug treatment formulation to a sinus, the method comprising
placing a needle syringe containing a drug formulation into a nasal cavity,
piercing a wall of the sinus with the needle syringe to form an opening,
inserting the needle syringe into the opening and
delivering the drug formulation to the sinus.

### Claim 3

A method of treating ethmoid sinusitis, comprising
piercing a wall of an ethmoid sinus with a needle syringe to form an opening,
inserting the needle syringe containing a treatment formulation through the opening into the ethmoid sinus and irrigating the ethmoid sinus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease is selected from the group consisting of acute, recurrent acute, chronic, infectious, allergic, polypoid sinusitis and rhinitis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the paranasal sinus is selected from the group consisting of a frontal sinus, an ethmoid sinus, a maxillary sinus and a sphenoid sinus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the treatment formulation is selected form the group consisting of an ophthalmic formulation and an irrigation solution.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treatment formulation is an ophthalmic formulation selected from the group consisting of an antibiotic, a steroid, an anti-viral, an antihistamine, a monoclonal antibody, a probiotic, an anti-fungal, a mast cell stabilizer, a mucolytic, a non-steroidal anti-inflammatory drug (NSAID), a vasoconstrictor, an immunosuppressant, an immune modulator, leukotriene inhibitors, bronchodilators, beta agonists, proteins, enzymes and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the treatment formulation is selected form the group consisting of an ophthalmic formulation and an irrigation solution.

### Claim 9 (depends on 2)

The method of claim 2, wherein delivering the occurs multiple times until symptoms resolve.

### Claim 10 (depends on 3)

The method of claim 3, wherein the disease is selected from the group consisting of acute, recurrent acute, chronic, infectious, allergic, polypoid sinusitis and rhinitis.

### Claim 11 (depends on 3)

The method of claim 3, wherein the irrigating bathes the ethmoid sinus in the treatment formulation.

### Claim 12

A composition for the treatment of sinusitis, said composition comprising at least one active pharmaceutical ingredient, a preservative and a buffered solution.

### Claim 13 (depends on 12)

The composition of claim 12, further comprising a penetration enhancer.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the composition is injected into a paranasal sinus selected from the consisting of a frontal sinus, an ethmoid sinus, a maxillary sinus and a sphenoid sinus.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the active pharmaceutical ingredient is selected from the group consisting of an antibiotic, a steroid, an anti-viral, an antihistamine, a monoclonal antibody, a probiotic, an anti-fungal, a mast cell stabilizer, a mucolytic, a non-steroidal anti-inflammatory drug (NSAID), a vasoconstrictor, an immunosuppressant, an immune modulator, leukotriene inhibitors, bronchodilators, beta agonists, proteins, enzymes and combinations thereof.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the active pharmaceutical ingredients are a combination of an antibiotic and a steroid.

### Claim 17 (depends on 12)

The composition of claim 12, wherein the preservatives are selected form the group consisting of benzylkonion chloride, chlorbutanol, phenylmercuric acetate and phenylmercuric nitrate.

### Claim 18

A kit comprising a first surgical tool forming an opening into a paranasal sinus; and
a second surgical tool including a prefilled syringe for delivery of a treatment formulation after an opening has been formed in the paranasal sinus.

### Claim 19

A kit comprising a prefilled syringe to attach to an endoscope for delivery of a treatment formulation after an opening has been formed in the paranasal sinus.
